Loading…

KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer

The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prog...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2024-01, Vol.15 (10), p.3140-3150
Main Authors: Han, Zhihang, Song, Chuanjun, Li, Dongqing, Zhu, Weiyou, Sun, Jiukang, Yao, Jialing, Gan, Wenyuan, Wang, Fufeng, Yang, Xiaodong, Zhu, Lingjun
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 3150
container_issue 10
container_start_page 3140
container_title Journal of Cancer
container_volume 15
creator Han, Zhihang
Song, Chuanjun
Li, Dongqing
Zhu, Weiyou
Sun, Jiukang
Yao, Jialing
Gan, Wenyuan
Wang, Fufeng
Yang, Xiaodong
Zhu, Lingjun
description The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with and mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P < 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the signaling network were also significantly associated with shortened PFS (univariate, P < 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02). mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.
doi_str_mv 10.7150/jca.94410
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11064249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3051427934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-ad30809d173d222bdd17c9d2198538b55a7779d24ebb143c51d24cb0b9622bb23</originalsourceid><addsrcrecordid>eNpVkU9PHSEUxUnTphrrol_AsLSLsfybYVgZ86LV1IlG7ZrcAd4TMw8UGBM_QL93seqLsuHccH7nkhyEvlNyIGlLft4ZOFBCUPIJbdOey0Z1nfj8Tm-h3ZzvSD1cMSn4V7TFe0k6Rftt9Pf3cMOO8DAXKD6GjCFYfOpXt_gyuUeYXDAOxyW2w3DVQM7ReCjObgCY8LVfBShzchXOFYurEHPxBp8F6w2UmDL2AQ-uQH6GDF7EKSZnSoUXUBekb-jLEqbsdl_vHfTn5PhmcdqcX_w6WxydN4bzrjRgOemJslRyyxgbbVVGWUZV3_J-bFuQUtZZuHGkgpuWVm1GMqquukfGd9DhS-79PK6dNS6UBJO-T34N6UlH8PrjS_C3ehUfNaWkE0yomrD_mpDiw-xy0WufjZsmCC7OWXPSUsGk4qJaf7xYTYo5J7fc7KFEP1ena3X6f3XVu_f-YxvnW1H8HyLFlhI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3051427934</pqid></control><display><type>article</type><title>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Han, Zhihang ; Song, Chuanjun ; Li, Dongqing ; Zhu, Weiyou ; Sun, Jiukang ; Yao, Jialing ; Gan, Wenyuan ; Wang, Fufeng ; Yang, Xiaodong ; Zhu, Lingjun</creator><creatorcontrib>Han, Zhihang ; Song, Chuanjun ; Li, Dongqing ; Zhu, Weiyou ; Sun, Jiukang ; Yao, Jialing ; Gan, Wenyuan ; Wang, Fufeng ; Yang, Xiaodong ; Zhu, Lingjun</creatorcontrib><description>The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with and mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P &lt; 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the signaling network were also significantly associated with shortened PFS (univariate, P &lt; 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02). mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.94410</identifier><identifier>PMID: 38706918</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Journal of Cancer, 2024-01, Vol.15 (10), p.3140-3150</ispartof><rights>The author(s).</rights><rights>The author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11064249/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11064249/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,36990,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38706918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Zhihang</creatorcontrib><creatorcontrib>Song, Chuanjun</creatorcontrib><creatorcontrib>Li, Dongqing</creatorcontrib><creatorcontrib>Zhu, Weiyou</creatorcontrib><creatorcontrib>Sun, Jiukang</creatorcontrib><creatorcontrib>Yao, Jialing</creatorcontrib><creatorcontrib>Gan, Wenyuan</creatorcontrib><creatorcontrib>Wang, Fufeng</creatorcontrib><creatorcontrib>Yang, Xiaodong</creatorcontrib><creatorcontrib>Zhu, Lingjun</creatorcontrib><title>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with and mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P &lt; 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the signaling network were also significantly associated with shortened PFS (univariate, P &lt; 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02). mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.</description><subject>Research Paper</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkU9PHSEUxUnTphrrol_AsLSLsfybYVgZ86LV1IlG7ZrcAd4TMw8UGBM_QL93seqLsuHccH7nkhyEvlNyIGlLft4ZOFBCUPIJbdOey0Z1nfj8Tm-h3ZzvSD1cMSn4V7TFe0k6Rftt9Pf3cMOO8DAXKD6GjCFYfOpXt_gyuUeYXDAOxyW2w3DVQM7ReCjObgCY8LVfBShzchXOFYurEHPxBp8F6w2UmDL2AQ-uQH6GDF7EKSZnSoUXUBekb-jLEqbsdl_vHfTn5PhmcdqcX_w6WxydN4bzrjRgOemJslRyyxgbbVVGWUZV3_J-bFuQUtZZuHGkgpuWVm1GMqquukfGd9DhS-79PK6dNS6UBJO-T34N6UlH8PrjS_C3ehUfNaWkE0yomrD_mpDiw-xy0WufjZsmCC7OWXPSUsGk4qJaf7xYTYo5J7fc7KFEP1ena3X6f3XVu_f-YxvnW1H8HyLFlhI</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Han, Zhihang</creator><creator>Song, Chuanjun</creator><creator>Li, Dongqing</creator><creator>Zhu, Weiyou</creator><creator>Sun, Jiukang</creator><creator>Yao, Jialing</creator><creator>Gan, Wenyuan</creator><creator>Wang, Fufeng</creator><creator>Yang, Xiaodong</creator><creator>Zhu, Lingjun</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</title><author>Han, Zhihang ; Song, Chuanjun ; Li, Dongqing ; Zhu, Weiyou ; Sun, Jiukang ; Yao, Jialing ; Gan, Wenyuan ; Wang, Fufeng ; Yang, Xiaodong ; Zhu, Lingjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-ad30809d173d222bdd17c9d2198538b55a7779d24ebb143c51d24cb0b9622bb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Zhihang</creatorcontrib><creatorcontrib>Song, Chuanjun</creatorcontrib><creatorcontrib>Li, Dongqing</creatorcontrib><creatorcontrib>Zhu, Weiyou</creatorcontrib><creatorcontrib>Sun, Jiukang</creatorcontrib><creatorcontrib>Yao, Jialing</creatorcontrib><creatorcontrib>Gan, Wenyuan</creatorcontrib><creatorcontrib>Wang, Fufeng</creatorcontrib><creatorcontrib>Yang, Xiaodong</creatorcontrib><creatorcontrib>Zhu, Lingjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Zhihang</au><au>Song, Chuanjun</au><au>Li, Dongqing</au><au>Zhu, Weiyou</au><au>Sun, Jiukang</au><au>Yao, Jialing</au><au>Gan, Wenyuan</au><au>Wang, Fufeng</au><au>Yang, Xiaodong</au><au>Zhu, Lingjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>15</volume><issue>10</issue><spage>3140</spage><epage>3150</epage><pages>3140-3150</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with and mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P &lt; 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the signaling network were also significantly associated with shortened PFS (univariate, P &lt; 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02). mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>38706918</pmid><doi>10.7150/jca.94410</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1837-9664
ispartof Journal of Cancer, 2024-01, Vol.15 (10), p.3140-3150
issn 1837-9664
1837-9664
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11064249
source PubMed (Medline); Publicly Available Content (ProQuest)
subjects Research Paper
title KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A06%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KMT2A%20Mutations%20and%20High%20Prevalence%20of%20dMMR-associated%20Mutational%20Signatures%20as%20Prognostic%20Indicators%20in%20Metastatic%20Colorectal%20Cancer&rft.jtitle=Journal%20of%20Cancer&rft.au=Han,%20Zhihang&rft.date=2024-01-01&rft.volume=15&rft.issue=10&rft.spage=3140&rft.epage=3150&rft.pages=3140-3150&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.94410&rft_dat=%3Cproquest_pubme%3E3051427934%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c336t-ad30809d173d222bdd17c9d2198538b55a7779d24ebb143c51d24cb0b9622bb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3051427934&rft_id=info:pmid/38706918&rfr_iscdi=true